United Therapeutics Corporation is a commercial-stage biotechnology company that develops targeted therapies for rare and life-threatening diseases. The company's core revenue is generated from its pulmonary arterial hypertension (PAH) franchise, which includes Tyvaso (nebulized and dry powder inhaler), Remodulin (subcutaneous and intravenous), and Orenitram (oral). It also markets Unituxin, a monoclonal antibody for the treatment of high-risk neuroblastoma. In 2024, the company generated $2.88 billion in total revenue, with Tyvaso products accounting for over $1.6 billion. Geographically, the vast majority of its revenue is derived from the United States. Beyond its established pharmaceutical portfolio, United Therapeutics is heavily invested in next-generation organ manufacturing technologies. This includes xenotransplantation using gene-edited porcine organs and 3D bioprinting of lung scaffolds, positioning the company as a pioneer in addressing the global organ shortage.
